Puma Biotechnology | PBYI - Operating Profit


Puma Biotechnology reported $22.08M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Moderna USD -857M 597M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Takeda JPY 168.82B 479.89B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025